| Date Filed | Type | Description |
| 08/18/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/10/2023 |
SC 13G
| Fairmount Funds Management LLC reports a 6.1% stake in Kiniksa Pharmaceuticals, Ltd. |
| 08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/25/2023 |
8-K
| Quarterly results |
| 06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/08/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in KINIKSA PHARMACEUTICALS LTD |
| 03/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 7.6% stake in Kiniksa Pharmaceuticals, Ltd. |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.3% stake in Kiniksa Pharmaceuticals Ltd. Class A |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/01/2022 |
8-K
| Quarterly results |
| 09/08/2022 |
SC 13G
| BlackRock Inc. reports a 5.1% stake in KINIKSA PHARMACEUTICALS LTD |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/03/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 05/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/18/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/24/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/24/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/22/2022 |
8-K
| Quarterly results|
Docs:
|
"KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue: Product revenue, net $ 18,745 $ — $ 38,544 $ — Operating expenses: Cost of goods sold 3,867 — 9,100 — Collaboration expenses 835 — 835 — Research and development 27,433 37,398 99,297 112,042 Selling, general and administrative 22,741 15,500 85,948 45,321 Total operating expenses 54,876 52,898 195,180 157,363 Loss from operations Interest income 77 30 97 1,134 Loss before provision for income taxes Provision for income taxes Net loss $ $ $ $ Net loss per share attributable to common shareholders —basic and diluted $ $ $ $ Weighted average common shares outstanding—basic and diluted 68,970,730 68,062,007 68,576,810 61,842,722 KINIKSA...",
"Huadong Medicine Investor and Media Contact" |
|
| 02/14/2022 |
SC 13G/A
| AMERIPRISE FINANCIAL INC reports a 0% stake in Kiniksa Pharmaceuticals, Ltd |
| 02/10/2022 |
SC 13G
| PICTET ASSET MANAGEMENT SA reports a 5.2% stake in Kiniksa Pharmaceuticals Ltd |
|